The market-leading choice for XIENCE™ Stent is everolimus, which is a proven therapeutic drug.²
An ideal drug for DES has these characteristics:
The everolimus drug provides all these features.
The release of everolimus aligns with the vessel's restenosis cascade. This, in turn, maximizes the drug's efficacy against restenosis and minimizes the drug's effect of re-endothelialization, which facilitates vessel restoration and function.
Everolimus Elution Correlates to Restenosis Cascade
Everolimus is a well established anti-proliferative drug. The concentration of everolimus used with XIENCE™ Stent is low, at 100 µg/cm². These histological images below show healthy, fully healed vessels at a concentration that is 8x the dose used on the XIENCE™ stent. Images were gathered using a pre-clinical animal model.
Everolimus Safety at 8x Drug Dose
MAT-2101779 v1.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.
Do you want to continue?